29 completed, 11 unknown, 7 terminated, 4 recruiting. 28 Phase 2, 9 Phase 1, 9 Phase 3, 6 Phase 4, 4 Not applicable.
Follow Deferoxamine: new trials by email Literature Review of Deferoxamine trials Research Report on Deferoxamine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Synergistic Minimally Invasive Surgery and Deferoxamine in ICH Minimally Invasive surgery (MIS), Deferoxamine, Standard Medical Care (SMD) - Intracerebral Hemorrhage, ICH - Intracerebral Hemorrhage | Phase 2 / Phase 3 | Not yet recruiting | University of Illinois at Chicago | 240 | 2026-03-01 | 2025-10-10 |
| Early Screening and Treatment of Heart Complication in Sickle Cell Disease Deferoxamine, Deferasirox, Deferiprone - Sickle Cell Disease | Phase 2 | Recruiting | Inova Health Care Services | 100 | 2025-10-07 | 2026-09-09 |
| The Fifth INTEnsive pReventing Secondary Injury in Acute Cerebral Haemorrhage Trial Within ACT-GLOBAL Colchicine 0.5 mg, Deferoxamine Mesylate, Control (Standard treatment) - Intracerebral Hemorrhage, Spontaneous Intracerebral Hemorrhage | Phase 3 | Recruiting | The George Institute | 2000 | 2025-02-27 | 2026-07-08 |
| Iron, Alpha-Synuclein, and Lymphocyte-activation Gene-3 in Ischemic Stroke Serum Iron, RBCs Alpha-synuclein, Serum Soluble lymphocyte activation gene - Brain Ischemia | Completed | Aswan University Hospital | 48 | 2023-04-01 | 2024-06-25 | |
| Comparison of Deferasirox and Desferoxamine in Patients of β-Thalassemia Major With Iron Overload Deferasirox (DFX), Deferoxamine (DFO) - Pateints of β-thalassemia Major With Iron Overload | Not applicable | Completed | RESnTEC, Institute of Research | 142 | 2023-01-01 | 2024-06-21 |
| Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers Deferoxamine, Placebo - Diabetic Foot Ulcer | Phase 2 | Unknown | Karolinska University Hospital | 174 | 2022-12-30 | 2022-05-26 |
| Deferoxamine in Aneurysmal Subarachnoid Hemorrhage Trial Deferoxamine, placebo - Intracranial Aneurysm, Subarachnoid Hemorrhage | Phase 1 / Phase 2 | Unknown | Radboud University Medical Center | 40 | 2022-12-02 | 2023-04-24 |
| Combined Antioxidant Therapy Against Myocardial Reperfusion Injury. Phase I Study. Antioxidant therapy, NaCl 0.9% - Acute Myocardial Infarction, Ischemia-reperfusion Injury | Phase 1 | Completed | University of Chile | 18 | 2022-08-09 | 2024-01-12 |
| Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer Deferoxamine Plus Chemotherapy - Triple Negative Breast Cancer | Phase 2 | Terminated | Sun Yat-sen University | 25 | 2022-03-21 | 2025-07-22 |
| Deferoxamine In the Treatment of Aneurysmal Subarachnoid Hemorrhage (aSAH) Deferoxamine, Placebo - Aneurysmal Subarachnoid Hemorrhage | Phase 2 | Recruiting | Aditya S. Pandey, MD | 120 | 2022-03-20 | 2026-11-12 |
| A Study of Deferoxamine (DFO) in People With Leptomeningeal Metastasis Deferoxamine (DFO) - Leptomeningeal Metastases | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 32 | 2021-12-22 | 2026-07-14 |
| Deferoxamine for the Prevention of Cardiac Surgery-Associated Acute Kidney Injury Deferoxamine, Normal saline - Acute Kidney Injury | Phase 2 | Completed | Brigham and Women's Hospital | 320 | 2021-04-13 | 2026-10-06 |
| Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia Tocilizumab Injection, Deferoxamine - COVID19, Intensive Care Unit | Phase 3 | Unknown | Abderrahmane Mami Hospital | 260 | 2020-09-04 | 2020-08-27 |
| Use of Desferal for Prevention of ARDS in Hospitalised Cases Documented With Covid 19 Infection Desferal 500 MG Injection - Covid 19 | Phase 4 | Unknown | Hesham Al-Inany | 200 | 2020-06-01 | 2020-05-15 |
| Application of Desferal to Treat COVID-19 Deferoxamine - COVID-19 | Phase 1 / Phase 2 | Unknown | Kermanshah University of Medical Sciences | 50 | 2020-04-01 | 2020-05-04 |
| Hydroxy Urea, Omega 3, Nigella Sativa,Honey on Oxidative Stress and Iron Chelation in Pediatric Major Thalassemia Omega 3, Nigella Sativa Oil, Hydroxyurea - Iron Overload, Oxidative Stress | Phase 2 / Phase 3 | Completed | Beni-Suef University | 350 | 2019-11-01 | 2021-01-27 |
| Evaluate the Efficacy and Safety of Irochel for the Management of Iron Overload in Thalassemia Patients in Comparison With Deferoxamine Irochel, Deferoxamine - Iron Overload Due to Repeated Red Blood Cell Transfusions, Thalassemia Majors (Beta-Thalassemia Major) | Phase 3 | Completed | Hamdard University | 132 | 2019-02-11 | 2026-08-25 |
| The Safety and Efficacy of Deferoxamine for Treating Unresectable Hepatocellular Carcinoma Conventional TACE, Deferoxamine and conventional TACE - Hepatocellular Carcinoma Non-resectable | Phase 1 | Unknown | Jinan Military General Hospital | 100 | 2018-09-01 | 2019-02-22 |
| Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes desferal, Isotonic saline - Diabetes Mellitus, Type 1 | Phase 2 | Unknown | Karolinska University Hospital | 30 | 2017-01-01 | 2022-05-26 |
| Deferoxamine and Xingnaojing Injection Treatment in Intracerebral Hemorrhage deferoxamine, Xingnaojing injection, Normal saline - Intracerebral Hemorrhage | Phase 1 / Phase 2 | Unknown | Capital Medical University | 180 | 2015-03-01 | 2015-05-18 |
Showing 20 of 52. Sign in to see all of them.
Iron Overload (18) · Thalassemia (12) · beta-Thalassemia (12) · Anemia, Sickle Cell (6) · Cerebral Hemorrhage (6) · Hemochromatosis (5) · Stroke (4) · COVID-19 (3) · Hemosiderosis (3) · Intracranial Hemorrhages (3) · Myelodysplastic Syndromes (3) · Subarachnoid Hemorrhage (3) · Acute Kidney Injury (2) · Anemia (2) · Cardiomyopathies (2)
Novartis Pharmaceuticals (7) · Beth Israel Deaconess Medical Center (3) · Brigham and Women's Hospital (3) · Ain Shams University (2) · ApoPharma (2) · Carelon Research (2) · Karolinska University Hospital (2) · Lipomed (2) · Abderrahmane Mami Hospital (1) · Aditya S. Pandey, MD (1) · Aga Khan University (1) · Aswan University Hospital (1) · Azienda Ospedaliera V. Cervello (1) · Beni-Suef University (1) · Boston Children's Hospital (1)
United States (21) · Canada (8) · Egypt (8) · China (5) · Italy (5) · Turkey (Türkiye) (4) · Greece (3) · Iran (3) · Pakistan (3) · United Kingdom (3) · Brazil (2) · Saudi Arabia (2) · Taiwan (2) · Thailand (2) · Tunisia (2)
Magdy Selim, MD, PhD (3) · Mohsen S. Elalfy, professour (2) · Patricia J. Giardina, MD (2) · Abraham IJ Gajardo, MD, PhD (1) · Aditya Pandey, MD (1) · Ahmed F Mahmoud Hussein, MS.c (1) · Alan R. Cohen, MD (1) · Amal M El-Beshlawy, Prof. Dr. (1) · Amir Kiani, PhD (1) · Antonio Piga, M.D. (1) · Asmaa Abdelmageed Muhammed (1) · Babar Hasan (1)
PMID 37975597, PMID 33236783, PMID 10051178, PMID 10669330, PMID 11886437, PMID 1406879, PMID 16787239, PMID 17233848, PMID 17951527, PMID 18055982, PMID 18351337, PMID 18369153, PMID 18552864, PMID 19236376, PMID 19724055, PMID 22045831, PMID 22180427, PMID 22187937, PMID 22547607, PMID 22609885, PMID 2265118, PMID 22875626, PMID 23151373, PMID 23943316, PMID 24385534, PMID 25076907, PMID 25291189, PMID 25345697, PMID 25492271, PMID 25600572, PMID 25934475, PMID 26304864, PMID 27745551, PMID 28583206, PMID 29619244, PMID 29719970, PMID 30898550, PMID 33758069, PMID 34439518, PMID 34789008, PMID 34847228, PMID 35306827, PMID 35676589, PMID 37807937, PMID 38689404, PMID 38973337, PMID 38979830, PMID 40399657, PMID 40418029, PMID 40789806
U01HL065232 (2), U01HL065238 (2), U01HL065239 (2), U01HL065244 (2), U01HL065260 (2), U01NS074425 (2), 2009 (1), K23AG030967 (1), R01DK125786 (1), R01NS057127 (1), U01HL065233 (1)